Why IMU is a multi multi bagger, page-25023

Thanks for the response Mason, I'd like to clear a few things up.
1) I am no expert in oncology, my background is CNS and Ophthalmology. I did not "know any better", my experience is just in clinical studies and drug development.
2) My opinion is that no data IMU has released to this point has been "bad". It has all shown some efficacy / response, however they are still in early stages with small patient numbers.
3) I've been invested in IMU (IUGNF here) via OTC since 2020 and during the run-up purchased my own block of shares at higher prices because I believed (and still believe) in the science of the company.
4) The ENTIRE biotech market has been a mess over the last few years. With interest rates being near zero a few years ago investment firms were pouring billions of dollars into spaces they had little experience and seeing great returns with mediocre data releases from companies. They are now very wary and even with good Phase 2 data we are seeing muted or negative responses. Promising Phase 3 with an clear runway to a PDUFA date / commerecialization is what really matters now.
and 5) For a little context, when I started at my most recent company back in 2020 we had a market cap of several billion dollars and NONE of our trials were in pivotal stages. We are now running several pivotal trials, have a BLA filing this year and continue to progress new candidates pre-clinically, yet our market cap is now well under $1B USD with more than 50% of that number in available cash (similar to IMU).

For those that bought this company during the run up because of FOMO, that is a lesson hard learned when the market overvalues anything. Early stage biotech is even more sensitive and just hurts that much more when it drops.

As many have echoed, clinical trials take time. Data cut, cleaning, and publication is time consuming and expensive and releasing partial data may be a nice assurance for investors, but Wall Street and the Australian Equivalent want high confidence these therapies are working and that requires many patients over a longer period of time.